PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (Nasdaq: PTCT) is a global biopharmaceutical company that discovers, develops and commercializes medicines for children and adults with rare disorders, primarily in neurology and metabolism. Its commercial products include Sephience for phenylketonuria, Emflaza and Translarna for Duchenne… From the company’s description.
Over the twelve months to Sep 30, 2026, PTC Therapeutics, Inc. reported revenue of $1.16B, down 35.1% from a year earlier, and a net loss of $105.97M. Its operating margin was 12.8%, and operations generated $10.49M in cash. In fiscal 2025, it reported revenue of $1.73B, up 114.5% from fiscal 2024, and net income of $682.64M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PTC Therapeutics, Inc. does
In the company’s own words
PTC Therapeutics, Inc. (Nasdaq: PTCT) is a global biopharmaceutical company that discovers, develops and commercializes medicines for children and adults with rare disorders, primarily in neurology and metabolism. Its commercial products include Sephience for phenylketonuria, Emflaza and Translarna for Duchenne muscular dystrophy, Upstaza and Kebilidi for AADC deficiency, and Tegsedi and Waylivra for rare diseases in Latin America and the Caribbean. Evrysdi, a spinal muscular atrophy treatment developed with Roche and the SMA Foundation, is marketed under a collaboration. The company also has clinical and preclinical programs, including votoplam for Huntington’s disease, which is partnered with Novartis, and vatiquinone for Friedreich’s ataxia. Its research platforms focus on RNA splicing and inflammation and ferroptosis; the company describes its business through these platforms and its commercial and development programs rather than reportable segments. Sephience is approved in the United States, Europe, Japan, Brazil and other geographies, while Upstaza is marketed in Europe and Kebilidi in the United States. Its website is www.ptcbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WARREN, NJ
- Fiscal year end
- December
- CIK
- 1070081
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PTC Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in PTC Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · PTC Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
PTC Therapeutics, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of PTC Therapeutics, Inc.’s debt, $87.61M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.50%, maturing 2026 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PTC Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PTC Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PTC Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”